This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Kathrin Plath | |
|---|---|
| Name | Kathrin Plath |
| Birth date | 1970s |
| Nationality | German |
| Fields | Cellular biology; Genetics |
| Institutions | Max Planck Society; University of Cambridge; University of California, Berkeley |
| Alma mater | Ludwig Maximilian University of Munich; University College London |
| Known for | Epigenetics; X chromosome inactivation; RNA biology |
Kathrin Plath is a German-born molecular biologist noted for her work on epigenetic regulation, X chromosome inactivation, and long noncoding RNA function. She has held positions at leading research centers and contributed to understanding mammalian dosage compensation, chromatin dynamics, and stem cell biology. Her work has intersected with research groups and programs across Europe and North America, informing studies in developmental biology, genetics, and disease modeling.
Plath was born in Germany in the 1970s and pursued higher education at institutions including Ludwig Maximilian University of Munich and University College London. During her doctoral studies she trained in laboratories engaged with chromatin biology, interacting with researchers from European Molecular Biology Laboratory, Max Planck Society, and university research institutes. Her graduate and postgraduate mentors included scientists working in fields connected to XIST RNA, Polycomb Repressive Complex 2, and transcriptional regulation, which set the stage for collaborations with groups at Harvard University, University of Cambridge, and Massachusetts Institute of Technology.
Plath’s academic appointments have included faculty and laboratory leadership roles at institutions such as the University of California, Los Angeles, the University of California, Berkeley, and affiliations with the Max Planck Society. She established independent research programs that partnered with centers like Wellcome Trust Sanger Institute, European Research Council, and clinical research units at hospitals affiliated with Charité – Universitätsmedizin Berlin. Her career trajectory involved collaborations with investigators at Stanford University, Yale University, and Cold Spring Harbor Laboratory, contributing to cross-institutional projects on mammalian development, epigenetic inheritance, and RNA-mediated regulation.
Plath’s research has focused on X chromosome inactivation (XCI) in mammals, the mechanisms of long noncoding RNAs such as XIST RNA, and the role of chromatin modifiers including Polycomb Repressive Complex 2 and histone methyltransferases. Her laboratory characterized molecular steps in initiation and maintenance of XCI, integrating insights from studies on embryonic stem cells, induced pluripotent stem cells, and early mammalian embryos. Plath’s work connected transcription factor networks involving proteins studied in labs at Cold Spring Harbor Laboratory and Broad Institute with epigenetic pathways defined by researchers at Max Planck Institute for Molecular Genetics and EMBL.
She contributed to elucidating how RNA-binding proteins, nuclear matrix components, and chromatin remodelers coordinate silencing across the X chromosome, drawing conceptual links to studies on long noncoding RNA function, nuclear architecture explored at European Molecular Biology Laboratory, and dosage compensation mechanisms compared with work in Drosophila melanogaster and Caenorhabditis elegans. Her publications influenced subsequent investigations into X-linked disease modeling, including research collaborations with clinicians at Johns Hopkins University and Massachusetts General Hospital on disorders involving sex chromosome aneuploidy.
As a professor and lab head, Plath supervised graduate students and postdoctoral fellows who subsequently joined academic groups at institutions such as University of Oxford, University of Cambridge, Harvard Medical School, and Columbia University. She taught courses on molecular biology techniques, epigenetics, and stem cell methods that referenced protocols used at Whitehead Institute, Broad Institute, and training centers like EMBL. Her mentorship emphasized experimental rigor, reproducibility standards promoted by organizations including Wellcome Trust and European Research Council, and career development linked to networks at National Institutes of Health and philanthropic funders such as the Gordon and Betty Moore Foundation.
Plath’s contributions have been recognized with awards and grants from bodies including the European Research Council, the Wellcome Trust, and national science foundations. She has received honors that align her with other leading investigators who study chromatin and RNA biology, joining networks supported by Gordon and Betty Moore Foundation, Human Frontier Science Program, and country-specific academies such as the German National Academy of Sciences Leopoldina. Her work has been invited for keynote lectures at meetings organized by societies like the American Society for Cell Biology, the European Molecular Biology Organization, and the International Society for Stem Cell Research.
- Plath K., et al., studies on initiation of X chromosome inactivation, journals associated with Cell Press, Nature Publishing Group, and collaborative labs at Harvard University and EMBL. - Plath K., contributions on long noncoding RNA mechanisms and chromatin modifiers, published alongside researchers from Massachusetts Institute of Technology and Stanford University. - Plath K., papers integrating stem cell models with epigenetic silencing, cited in work from Broad Institute and clinical studies at Massachusetts General Hospital.
Category:German biologists Category:Epigeneticists